Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and Gemtuzumab Ozogamicin in Newly Diagnosed AML
NCT05558124Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin + cytarabine liposome and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 18 Months. Started Feb 2023; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposomegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05558124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558124.